Kymera Therapeutics Inc
NASDAQ:KYMR

Watchlist Manager
Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc
NASDAQ:KYMR
Watchlist
Price: 40.66 USD 3.88% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Kymera Therapeutics Inc?
Write Note

Intrinsic Value

KYMR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one KYMR stock under the Base Case scenario is 10.78 USD. Compared to the current market price of 40.66 USD, Kymera Therapeutics Inc is Overvalued by 73%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KYMR Intrinsic Value
10.78 USD
Overvaluation 73%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Kymera Therapeutics Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
KYMR
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for KYMR cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about KYMR?
Bearish
Neutral
Bullish

Fundamental Analysis

40.66 USD
+3.88%
+3.88%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Kymera Therapeutics Inc
US
Biotechnology
Market Cap
2.6B USD
IPO
Aug 21, 2020
Employees
136
United States of America
Market Cap
2.6B USD
Industry
Biotechnology
IPO
Aug 21, 2020
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Kymera Therapeutics Inc

Provide an overview of the primary business activities
of Kymera Therapeutics Inc.

What unique competitive advantages
does Kymera Therapeutics Inc hold over its rivals?

What risks and challenges
does Kymera Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Kymera Therapeutics Inc recently?

Summarize the latest earnings call
of Kymera Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kymera Therapeutics Inc.

Provide P/S
for Kymera Therapeutics Inc.

Provide P/E
for Kymera Therapeutics Inc.

Provide P/OCF
for Kymera Therapeutics Inc.

Provide P/FCFE
for Kymera Therapeutics Inc.

Provide P/B
for Kymera Therapeutics Inc.

Provide EV/S
for Kymera Therapeutics Inc.

Provide EV/GP
for Kymera Therapeutics Inc.

Provide EV/EBITDA
for Kymera Therapeutics Inc.

Provide EV/EBIT
for Kymera Therapeutics Inc.

Provide EV/OCF
for Kymera Therapeutics Inc.

Provide EV/FCFF
for Kymera Therapeutics Inc.

Provide EV/IC
for Kymera Therapeutics Inc.

Show me price targets
for Kymera Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Kymera Therapeutics Inc?

How accurate were the past Revenue estimates
for Kymera Therapeutics Inc?

What are the Net Income projections
for Kymera Therapeutics Inc?

How accurate were the past Net Income estimates
for Kymera Therapeutics Inc?

What are the EPS projections
for Kymera Therapeutics Inc?

How accurate were the past EPS estimates
for Kymera Therapeutics Inc?

What are the EBIT projections
for Kymera Therapeutics Inc?

How accurate were the past EBIT estimates
for Kymera Therapeutics Inc?

Compare the revenue forecasts
for Kymera Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kymera Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kymera Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kymera Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Kymera Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kymera Therapeutics Inc with its peers.

Analyze the financial leverage
of Kymera Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Kymera Therapeutics Inc.

Provide ROE
for Kymera Therapeutics Inc.

Provide ROA
for Kymera Therapeutics Inc.

Provide ROIC
for Kymera Therapeutics Inc.

Provide ROCE
for Kymera Therapeutics Inc.

Provide Gross Margin
for Kymera Therapeutics Inc.

Provide Operating Margin
for Kymera Therapeutics Inc.

Provide Net Margin
for Kymera Therapeutics Inc.

Provide FCF Margin
for Kymera Therapeutics Inc.

Show all solvency ratios
for Kymera Therapeutics Inc.

Provide D/E Ratio
for Kymera Therapeutics Inc.

Provide D/A Ratio
for Kymera Therapeutics Inc.

Provide Interest Coverage Ratio
for Kymera Therapeutics Inc.

Provide Altman Z-Score Ratio
for Kymera Therapeutics Inc.

Provide Quick Ratio
for Kymera Therapeutics Inc.

Provide Current Ratio
for Kymera Therapeutics Inc.

Provide Cash Ratio
for Kymera Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Kymera Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Kymera Therapeutics Inc?

What is the current Free Cash Flow
of Kymera Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kymera Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kymera Therapeutics Inc

Current Assets 568.7m
Cash & Short-Term Investments 550m
Receivables 1.3m
Other Current Assets 17.4m
Non-Current Assets 466.1m
Long-Term Investments 361m
PP&E 99.3m
Other Non-Current Assets 5.8m
Current Liabilities 66.5m
Accounts Payable 6.5m
Accrued Liabilities 37m
Other Current Liabilities 23m
Non-Current Liabilities 75.4m
Long-Term Debt 1.7m
Other Non-Current Liabilities 73.6m
Efficiency

Earnings Waterfall
Kymera Therapeutics Inc

Revenue
87.6m USD
Operating Expenses
-282.8m USD
Operating Income
-195.3m USD
Other Expenses
27.8m USD
Net Income
-167.5m USD

Free Cash Flow Analysis
Kymera Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

KYMR Profitability Score
Profitability Due Diligence

Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
Declining ROE
Declining ROIC
20/100
Profitability
Score

Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

KYMR Solvency Score
Solvency Due Diligence

Kymera Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Kymera Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KYMR Price Targets Summary
Kymera Therapeutics Inc

Wall Street analysts forecast KYMR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KYMR is 60.18 USD with a low forecast of 41.41 USD and a high forecast of 94.5 USD.

Lowest
Price Target
41.41 USD
2% Upside
Average
Price Target
60.18 USD
48% Upside
Highest
Price Target
94.5 USD
132% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KYMR?

Click here to dive deeper.

Dividends

Kymera Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KYMR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KYMR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

KYMR News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one KYMR stock?

The intrinsic value of one KYMR stock under the Base Case scenario is 10.78 USD.

Is KYMR stock undervalued or overvalued?

Compared to the current market price of 40.66 USD, Kymera Therapeutics Inc is Overvalued by 73%.

Back to Top